• head_banner_01

OEM/ODM Supplier Bromoethylamine Hydrobromide - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Persisting in "High top quality, Prompt Delivery, Aggressive Price", now we have established long-term cooperation with customers from the two overseas and domestically and get new and aged clients' large comments for Escitalopram Oxalate, Niraparib, Calcium Magnesium Acetate, With a wide range, good quality, realistic charges and stylish designs,Our products and solutions are widely recognized and trusted by users and can fulfill continuously changing economic and social needs.
OEM/ODM Supplier Bromoethylamine Hydrobromide - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:

Product Detail

Name  Eptifibatide
CAS number  188627-80-7
Molecular formula  C35H49N11O9S2
Molecular weight  831.96
EINECS Number  641-366-7
Density  1.60±0.1 g/cm3(Predicted)
Storage conditions  Sealed in dry, store in freezer, under -15°C

Synonyms

Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).

Platelet Glycoprotein Antagonist

Etifibatide (integrilin) ​​is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.

Classification

Classification of Antiplatelet Aggregation Drugs

Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.


Product detail pictures:

OEM/ODM Supplier Bromoethylamine Hydrobromide - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex detail pictures

OEM/ODM Supplier Bromoethylamine Hydrobromide - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex detail pictures


Related Product Guide:

Our primary goal is to offer our clients a serious and responsible business relationship, providing personalized attention to all of them for OEM/ODM Supplier Bromoethylamine Hydrobromide - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: Nepal, Honduras, Serbia, To meet the requirements of individual customers for each bit more perfect service and stable quality products. We warmly welcome customers around the world to visit us, with our multi-faceted cooperation, and jointly develop new markets, create a brilliant future!
  • With a positive attitude of "regard the market, regard the custom, regard the science", the company works actively to do research and development. Hope we have a future business relationships and achieving mutual success.
    5 Stars By Leona from Lahore - 2017.06.19 13:51
    The supplier cooperation attitude is very good, encountered various problems, always willing to cooperate with us, to us as the real God.
    5 Stars By Martin Tesch from Azerbaijan - 2018.11.04 10:32
    Write your message here and send it to us